Gait analysis using Wearable Sensors: different gait metrics can differentiate Parkinson’s Disease Patients from Healthy Controls and Parkinson’s Disease patients in different medication status
Objective: To identify which gait metrics better distinguish PD-OFF from PD Best-ON and PD from HC, using a dimensionality-reduction method Background: Objective gait analysis using…Clinical Characteristics of patients with Parkinson’s disease showing normal values on SBR in the DAT SPECT
Objective: The aim of this study was to clarify what the ‘normal’ values of the specific binding ratio (SBR), a measure of striatal radiotracer uptake…Quality of life and patient reported outcomes with subcutaneous levodopa/carbidopa infusion: Findings from the ND0612 BeyoND study
Objective: To review quality of life and other patient reported outcomes data from the ND0612 BeyoND study. Background: ND0612 is in development as a continuous,…Can we add whey protein supplementation in patients with Parkinson’s disease without interfering with levodopa response?
Objective: The main endpoint of the study was to evaluate if a daily intake of whey protein-based dietary supplement causes a worse response to levodopa…Response of freezing, posture and voice to increasing levodopa doses in Parkinson’s disease
Objective: To analyze the resistance to high levodopa doses of FoG, posture, speech, and gait features in PD patients during a daily-ON therapeutic condition. Background:…Long-term safety of continuous levodopa/carbidopa infusion with ND0612: Data from patients who continued past one year in the BeyoND study
Objective: To report long-term safety and tolerability data from the ongoing BeyoND study (NCT02726386) for patients who continued treatment past the one-year primary endpoint. Background:…The effect of co-administration of opicapone on the pharmacokinetics of levodopa
Objective: Few studies have examined levodopa (LD) pharmacokinetics in combination with opicapone (OPC) in Japanese patients with Parkinson's disease (PD). Therefore, we investigated changes in…IPX203 dose conversion from immediate-release carbidopa-levodopa, in Parkinson’s disease patients with motor fluctuations.
Objective: To analyze dosing regimen data from a Phase 3 study in order to identify an optimal dose conversion from IR CD-LD to IPX203 for…Impact of istradefylline on the adjustment of levodopa dose escalation in Parkinson’s disease: Results of the ISTRA ADJUST PD randomized, controlled study
Objective: To evaluate the effect of istradefylline (IST), an adenosine A2A receptor antagonist, on the adjustment of levodopa dose escalation in patients with Parkinson’s disease…Levodopa–entacapone–carbidopa intestinal gel infusion for advanced Parkinson’s disease patients – data from a Romanian center
Objective: To report the experience with levodopa–entacapone–carbidopa intestinal gel infusion (LECIG) for the management of advanced Parkinson’s disease (PD) from a Romanian center. Background: LECIG…
- « Previous Page
- 1
- …
- 16
- 17
- 18
- 19
- 20
- …
- 62
- Next Page »